{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:07Z","timestamp":1793018107424,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10072-026-09435-0","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:30:54Z","timestamp":1792726254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["APOE \u03b54 accelerates plasma p-tau217 trajectory: a Bayesian joint longitudinal analysis of ADNI"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-4220","authenticated-orcid":false,"given":"Kuan-Yu","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"2","key":"9435_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","unstructured":"GBD 2019 Dementia Forecasting Collaborators (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7(2):e105\u2013e125. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8","journal-title":"Lancet Public Health"},{"issue":"1","key":"9435_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","volume":"15","author":"DP Veitch","year":"2019","unstructured":"Veitch DP, Weiner MW, Aisen PS et al (2019) Understanding disease progression and improving Alzheimer\u2019s disease clinical trials: recent highlights from the Alzheimer\u2019s Disease Neuroimaging Initiative. Alzheimers Dement 15(1):106\u2013152. https:\/\/doi.org\/10.1016\/j.jalz.2018.08.005","journal-title":"Alzheimers Dement"},{"issue":"4","key":"9435_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"issue":"8","key":"9435_CR4","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"issue":"9","key":"9435_CR5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S et al (2023) A two-step workflow based on plasma p-tau217 to screen for amyloid-\u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging 3(9):1079\u20131090. https:\/\/doi.org\/10.1038\/s43587-023-00471-5","journal-title":"Nat Aging"},{"issue":"7638","key":"9435_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541(7638):481\u2013487. https:\/\/doi.org\/10.1038\/nature21029","journal-title":"Nature"},{"issue":"6","key":"9435_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41593-020-0624-8","volume":"23","author":"N Habib","year":"2020","unstructured":"Habib N, McCabe C, Medina S et al (2020) Disease-associated astrocytes in Alzheimer\u2019s disease and aging. Nat Neurosci 23(6):701\u2013706. https:\/\/doi.org\/10.1038\/s41593-020-0624-8","journal-title":"Nat Neurosci"},{"issue":"7","key":"9435_CR8","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Povala G, Ferreira PCL et al (2023) Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat Med 29(7):1775\u20131781. https:\/\/doi.org\/10.1038\/s41591-023-02380-x","journal-title":"Nat Med"},{"issue":"1","key":"9435_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J et al (2021) Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future cognitive decline in mild cognitive impairment. Alzheimers Res Ther 13(1):68. https:\/\/doi.org\/10.1186\/s13195-021-00804-9","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"9435_CR10","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R et al (2021) Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 144(11):3505\u20133516. https:\/\/doi.org\/10.1093\/brain\/awab223","journal-title":"Brain"},{"issue":"12","key":"9435_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 78(12):1471\u20131483. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671","journal-title":"JAMA Neurol"},{"issue":"1","key":"9435_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","volume":"11","author":"P Chatterjee","year":"2021","unstructured":"Chatterjee P, Pedrini S, Stoops E et al (2021) Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease. Transl Psychiatry 11(1):27. https:\/\/doi.org\/10.1038\/s41398-020-01137-1","journal-title":"Transl Psychiatry"},{"issue":"7","key":"9435_CR13","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD et al (2022) Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med 28(7):1398\u20131405. https:\/\/doi.org\/10.1038\/s41591-022-01822-2","journal-title":"Nat Med"},{"issue":"8","key":"9435_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT et al (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324(8):772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134","journal-title":"JAMA"},{"issue":"5","key":"9435_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK et al (2021) Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol 141(5):709\u2013724. https:\/\/doi.org\/10.1007\/s00401-021-02275-6","journal-title":"Acta Neuropathol"},{"issue":"3","key":"9435_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G et al (2024) Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol 81(3):255\u2013263. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319","journal-title":"JAMA Neurol"},{"issue":"2","key":"9435_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S et al (2023) Association of phosphorylated tau biomarkers with amyloid PET vs tau PET. JAMA Neurol 80(2):188\u2013199. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485","journal-title":"JAMA Neurol"},{"issue":"2","key":"9435_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R et al (2021) Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol 78(2):149\u2013156. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4201","journal-title":"JAMA Neurol"},{"issue":"1","key":"9435_CR19","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","volume":"12","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Janelidze S et al (2021) Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun 12(1):3555. https:\/\/doi.org\/10.1038\/s41467-021-23746-0","journal-title":"Nat Commun"},{"issue":"4","key":"9435_CR20","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ et al (2023) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer disease. Brain 146(4):1592\u20131601. https:\/\/doi.org\/10.1093\/brain\/awac333","journal-title":"Brain"},{"issue":"11","key":"9435_CR21","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ (2020) Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med 217(11):e20200861. https:\/\/doi.org\/10.1084\/jem.20200861","journal-title":"J Exp Med"},{"issue":"11","key":"9435_CR22","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S et al (2020) Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 143(11):3234\u20133241. https:\/\/doi.org\/10.1093\/brain\/awaa286","journal-title":"Brain"},{"issue":"1","key":"9435_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 20(1):68\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(20)30412-9","journal-title":"Lancet Neurol"},{"issue":"5","key":"9435_CR24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea J, Pegueroles J, Alcolea D et al (2024) APOE4 homozygosity represents a distinct genetic form of Alzheimer\u2019s disease. Nat Med 30(5):1284\u20131291. https:\/\/doi.org\/10.1038\/s41591-024-02931-w","journal-title":"Nat Med"},{"issue":"5","key":"9435_CR25","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, Bateman RJ, Hansson O (2023) Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol 80(5):516\u2013522. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199","journal-title":"JAMA Neurol"},{"key":"9435_CR26","doi-asserted-by":"publisher","DOI":"10.1201\/b12208","volume-title":"Joint models for longitudinal and time-to-event data: with applications in R","author":"D Rizopoulos","year":"2012","unstructured":"Rizopoulos D (2012) Joint models for longitudinal and time-to-event data: with applications in R. Chapman & Hall\/CRC, Boca Raton, FL"},{"issue":"3","key":"9435_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA et al (2010) Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 74(3):201\u2013209","journal-title":"Neurology"},{"issue":"5","key":"9435_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2016.10.006","volume":"13","author":"MW Weiner","year":"2017","unstructured":"Weiner MW, Veitch DP, Aisen PS et al (2017) The Alzheimer\u2019s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement 13(5):561\u2013571. https:\/\/doi.org\/10.1016\/j.jalz.2016.10.006","journal-title":"Alzheimers Dement"},{"issue":"6","key":"9435_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG et al (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28(6):595\u2013599. https:\/\/doi.org\/10.1038\/nbt.1641","journal-title":"Nat Biotechnol"},{"issue":"Suppl 2","key":"9435_CR30","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","volume":"11","author":"RC Mohs","year":"1997","unstructured":"Mohs RC, Knopman D, Petersen RC et al (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope. Alzheimer Dis Assoc Disord 11(Suppl 2):S13\u2013S21","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"9435_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-mental state\u201d: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189\u2013198","journal-title":"J Psychiatr Res"},{"issue":"2","key":"9435_CR32","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl B (2012) FreeSurfer. Neuroimage 62(2):774\u2013781. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.01.021","journal-title":"Neuroimage"},{"issue":"19","key":"9435_CR33","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J et al (2021) New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385(19):1737\u20131749. https:\/\/doi.org\/10.1056\/NEJMoa2102953","journal-title":"N Engl J Med"},{"issue":"2","key":"9435_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v078.i02","volume":"78","author":"C Proust-Lima","year":"2017","unstructured":"Proust-Lima C, Philipps V, Liquet B (2017) Estimation of extended mixed models using latent classes and latent processes: the R package lcmm. J Stat Softw 78(2):1\u201356. https:\/\/doi.org\/10.18637\/jss.v078.i02","journal-title":"J Stat Softw"},{"issue":"1","key":"9435_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v080.i01","volume":"80","author":"PC B\u00fcrkner","year":"2017","unstructured":"B\u00fcrkner PC (2017) brms: An R package for Bayesian multilevel models using Stan. J Stat Softw 80(1):1\u201328. https:\/\/doi.org\/10.18637\/jss.v080.i01","journal-title":"J Stat Softw"},{"issue":"4","key":"9435_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1037\/a0020761","volume":"15","author":"K Imai","year":"2010","unstructured":"Imai K, Keele L, Tingley D (2010) A general approach to causal mediation analysis. Psychol Methods 15(4):309\u2013334. https:\/\/doi.org\/10.1037\/a0020761","journal-title":"Psychol Methods"},{"issue":"1","key":"9435_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 57(1):289\u2013300","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"1","key":"9435_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67(1):1\u201348. https:\/\/doi.org\/10.18637\/jss.v067.i01","journal-title":"J Stat Softw"},{"issue":"10","key":"9435_CR39","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG et al (2007) STROBE: explanation and elaboration. PLoS Med 4(10):e297","journal-title":"PLoS Med"},{"key":"9435_CR40","doi-asserted-by":"publisher","unstructured":"Cousins KAQ, Korecka M, Wan Y, Vulaj A et al (2025) Comparison of plasma p-tau217\/A\u03b242, p-tau217, and A\u03b242\/A\u03b240 biomarkers by race to detect Alzheimer's disease. Alzheimers Dement 21(8):e70469. https:\/\/doi.org\/10.1002\/alz.70469","DOI":"10.1002\/alz.70469"},{"issue":"12","key":"9435_CR41","doi-asserted-by":"publisher","first-page":"e71048","DOI":"10.1002\/alz.71048","volume":"21","author":"MS Woo","year":"2025","unstructured":"Woo MS, Macedo AC, Hosseini SA et al (2025) APOE \u03b54 carriership determines a faster plasma p-tau217 progression in A\u03b2-positive individuals. Alzheimers Dement 21(12):e71048. https:\/\/doi.org\/10.1002\/alz.71048","journal-title":"Alzheimers Dement"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09435-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09435-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09435-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:03:08Z","timestamp":1793016188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09435-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["9435"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09435-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"6 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used de-identified data from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). ADNI study procedures were approved by the institutional review board at each participating site, and the study was conducted in accordance with the Declaration of Helsinki. No new ethics approval was required for this secondary analysis.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all ADNI participants (or their authorized representatives) at the time of enrollment, as described in the original ADNI protocol. No new consent was required for this secondary analysis of de-identified data.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the author used Claude, a large language model-based AI assistant, to assist with statistical code development, execution, and debugging, generation and editing of figures and tables, and drafting and language editing of the manuscript text. After using this tool, the author reviewed, independently verified against the underlying data and code, and edited all content, and takes full responsibility for the content of this publication.","order":4,"name":"Ethics","label":"Declaration of Generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"883"}}